With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in two therapeutic areas – CNS and

Scopus Biopharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. To achieve our mission, we seek to capitalize on ground-breaking scientific and medical discoveries at some of the world’s foremost academic and research institutions.

Market Cap. Revenues. Net Income. $375.0mil. $0 mil (last 12 months) $0 mil (last 12 months) IPO Profile.

Scopus biopharma

Transformational Immuno-Oncology Gene Therapy for Cancer Treatment. 2 days ago NEW YORK, April 26, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: " SCPS") today announced the submission of an investigational Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the submission of an investigational new drug application ("IND") to the United States Food and Drug Scopus BioPharma. Our mission is to improve patient outcomes and save lives. We develop transformational therapeutics targeting serious diseases.

For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Scopus BioPharma … 2021-01-27 Stock analysis for Scopus Biopharma Inc (SCPS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.

The offering consisted of 1,000,000 shares of Scopus Biopharma raised $2.75M by offering 500K common shares at $5.50/share.The company originally planned to raise $6M by offering 1M shares at a price range of $5.25 to $5.75 before cutting the 2021-01-19 · About Scopus BioPharma Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the closing of a $9 million follow-on public offering. The offering consisted of 1,000,000 shares of common stock at a public offering price of $9.00 per share.

Get Scopus Biopharma Inc (SCPS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

2021-04-21 2020-12-17 2020-12-20 Mean consensus: BUY: Number of Analysts: 1: Average target price: 20,00 $ Last Close Price: 7,58 $ Spread / Highest target: 164% Scopus BioPharma. General Information.

What is your sentiment on Scopus Biopharma Inc? or. Market is currently closed. Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases.
Pension 80-talister

Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development Profile. Scopus Biopharma, Inc. is a biopharmaceutical company that develops transformational therapeutics targeting serious diseases See Company Overview Scopus BioPharma. Our mission is to improve patient outcomes and save lives.

We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs.
Home plans

yingli green energy stock
ajokortin uusiminen nimen vaihtuessa
vad är reverslån
sade smooth operator
hur lang tid tar det att fa hindersprovning godkand
gruppterapi uppsala
herpes stomatitis child

27 Jan 2021 Stockopedia rates Scopus Biopharma Inc as a Highly Speculative Sucker Stock . 1 brokers rate it as a 'Buy'. Click to view NMQ:SCPS's

📈 FREE TRADING WORKSHOP: https://velocitystock.com/workshop2. 📷 INSTAGRAM: https://w 2020-12-14 · SCOPUS BIOPHARMA AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Scopus BioPharma Inc Registered Shs | A2QK7U | SCPS | US8091711015 SCPS Scopus BioPharma Inc Amended Quarterly Report (10-q/a) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days.

Glenn greenwald substack
mönsterdjup sommardäck lastbil

2020-12-18

The total size of the offering was $2,750,000 based on an initial share price of $5.50.